^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Squamous Cell Skin Cancer

    Related cancers:
    1d
    KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma. (PubMed, Mol Ther Oncol)
    Similar findings were observed in metastatic lymph nodes, demonstrating viral activity and tumor suppression. Collectively, these results indicate that KLS-3021 exerts potent anti-tumor efficacy in both primary and metastatic cSCC models, supporting its clinical translation as a multifunctional oncolytic virotherapy targeting the physical and immunological barriers of the tumor microenvironment.
    Journal
    |
    PD-1 (Programmed cell death 1)
    5d
    Comparative single cell analysis of wound and cancer identifies the metabolic dialogues between tumor initiating stem cells and macrophages. (PubMed, bioRxiv)
    Critically, our genetic manipulations allow us to identify SOX2 High tumor-initiating stem cells as key orchestrators that modulate the lipid metabolism of TAMs and shape their cell states. These findings suggest that disrupting the metabolic crosstalk between tumor-initiating stem cells and TAMs represents a promising strategy to normalize myeloid cell function and enhance cancer immunotherapy efficacy.
    Journal
    |
    SOX2
    6d
    NCI-2018-01055: Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy (clinicaltrials.gov)
    P2, N=62, Completed, Roswell Park Cancer Institute | Phase classification: P=N/A --> P2
    Phase classification • HEOR
    7d
    A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers (clinicaltrials.gov)
    P1/2, N=398, Recruiting, Hummingbird Bioscience | N=98 --> 398 | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2026 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Erbitux (cetuximab) • docetaxel • HMBD-001
    7d
    WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma. (PubMed, Proc Natl Acad Sci U S A)
    Functional assays in human keratinocytes and cSCC cells further showed that WWOX depletion enhances EMT plasticity, invasiveness, and metastatic colonization. Together, these findings identify WWOX as a critical regulator of epidermal integrity and reveal a previously unrecognized WWOX-p63 axis that constrains EMT and tumor progression in cSCC.
    Journal
    |
    TP63 (Tumor protein 63) • WWOX (WW Domain Containing Oxidoreductase)
    9d
    Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study (clinicaltrials.gov)
    P2, N=174, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin
    17d
    Integrative multi-omics identifies a diagnostic T cell signature for cutaneous squamous cell carcinoma. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Specifically, CYBA and S100A2 are identified as promising diagnostic candidate signatures, while APOE may reflect immunomodulatory heterogeneity. These findings offer insights for developing diagnostic strategies and targeted immunotherapies in cSCC.
    Journal • IO biomarker
    |
    FOXP3 (Forkhead Box P3) • APOE (Apolipoprotein E)
    21d
    Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=25, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Sep 2026 --> Feb 2027
    Trial primary completion date
    |
    Gilotrif (afatinib)
    21d
    A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=63, Completed, Incyte Corporation | Recruiting --> Completed
    Trial completion
    |
    INCB99280
    23d
    ETCABIO: Evaluation of Skin Tests in Biotherapy Allergies (clinicaltrials.gov)
    P=N/A, N=70, Not yet recruiting, University Hospital, Angers | Trial completion date: Oct 2027 --> Jun 2028 | Initiation date: Sep 2025 --> May 2026 | Trial primary completion date: Sep 2027 --> May 2028
    Trial completion date • Trial initiation date • Trial primary completion date